Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LNCR3
MCID: LNG064
MIFTS: 70

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Cancer Susceptibility 3

About this section

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 57 13 70
Lung Adenocarcinoma 12 20 29 6 15 17
Adenocarcinoma of Lung 57 12 73 44 70
Adenocarcinoma of Lung, Susceptibility to 57
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 70
Nonsmall Cell Adenocarcinoma 12
Lung Adenocarcinomas 15
Adenocarcinoma Lung 54
Lncr3 57

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3910
OMIM® 57 612571
MeSH 44 D000077192
NCIt 50 C27745 C3512
SNOMED-CT 67 254626006
UMLS 70 C0152013 C1335060 C2675497
Sources

Summaries for Lung Cancer Susceptibility 3

About this section
GARD : 20 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting.

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to lung cancer and lung squamous cell carcinoma. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are MAPK Pathway and Bladder cancer. The drugs Endostar protein and Endostatins have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and lymph node.

Disease Ontology : 12 A lung non-small cell carcinoma that derives from epithelial cells of glandular origin.

Wikipedia : 73 Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer,... more...

More information from OMIM: 612571
Sources

Related Diseases for Lung Cancer Susceptibility 3

About this section

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 750)
# Related Disease Score Top Affiliating Genes
1 lung cancer 33.9 TUG1 ROS1 PRKN MALAT1 LINC-ROR HOTAIR
2 lung squamous cell carcinoma 32.9 TUG1 ROS1 EGFR CCAT1 BRAF
3 high grade glioma 32.8 TUG1 MALAT1 LINC-ROR HOTAIR GAS5 EGFR
4 adenocarcinoma 32.1 ROS1 MALAT1 HNF1A-AS1 ERBB2 EGFR BRAF
5 hepatocellular carcinoma 31.8 TUG1 MALAT1 LINC00941 LINC-ROR HOTAIR HNF1A-AS1
6 small cell cancer of the lung 31.8 TUG1 MALAT1 HOTAIR EGFR
7 gastric cancer 31.8 TUG1 MALAT1 LINC00941 LINC-ROR HOTAIR HNF1A-AS1
8 thyroid carcinoma 31.7 MALAT1 HOTAIR GAS5 BRAF AFAP1-AS1
9 glioblastoma 31.6 TUG1 ROS1 MALAT1 HOTAIR GAS5 ERBB2
10 renal cell carcinoma, nonpapillary 31.6 TUG1 MALAT1 LINC-ROR HOTAIR GAS5 EGFR
11 esophageal cancer 31.6 MIR375 MALAT1 LINC-ROR HOTAIR GAS5 ERBB2
12 melanoma 31.5 MALAT1 LINC-ROR HOTAIR GAS5 ERBB2 EGFR
13 bladder cancer 31.5 TUG1 MALAT1 HOTAIR HNF1A-AS1 GAS5 ERBB2
14 large cell carcinoma 31.5 ROS1 ERBB2 EGFR
15 osteogenic sarcoma 31.5 TUG1 MALAT1 HOTAIR HNF1A-AS1 GAS5 FENDRR
16 thyroid cancer, nonmedullary, 1 31.5 MALAT1 LINC-ROR HOTAIR BRAF
17 glioma 31.5 MALAT1 HOTAIR GAS5 ERBB2 EGFR CYTOR
18 squamous cell carcinoma 31.4 TUG1 MALAT1 HOTAIR HNF1A-AS1 ERBB2 EGFR
19 colorectal cancer 31.4 TUG1 ROS1 MIR375 MALAT1 LINC00472 LINC-ROR
20 cholangiocarcinoma 31.4 TUG1 ROS1 MALAT1 ERBB2 EGFR BRAF
21 ovarian cancer 31.3 TUG1 PRKN MALAT1 LINC00472 LINC-ROR HOTAIR
22 nasopharyngeal carcinoma 31.3 MALAT1 LINC-ROR HOTAIR HNF1A-AS1 GAS5 EGFR
23 oral squamous cell carcinoma 31.2 TUG1 MALAT1 HOTAIR EGFR CCAT1
24 kidney cancer 31.2 MALAT1 HOTAIR GAS5 EGFR
25 intrahepatic cholangiocarcinoma 31.2 TUG1 ERBB2 EGFR CCAT1
26 pancreatic cancer 31.2 TUG1 MIR375 MALAT1 LINC-ROR HOTAIR HNF1A-AS1
27 myeloma, multiple 31.1 TUG1 MALAT1 HOTAIR GAS5 ERBB2 EGFR
28 endometrial cancer 31.1 TUG1 LINC-ROR HOTAIR GAS5 ERBB2 EGFR
29 paronychia 31.1 ERBB2 EGFR
30 skin melanoma 31.0 ROS1 ERBB2 EGFR BRAF
31 cervical cancer 31.0 TUG1 MALAT1 HOTAIR GAS5 ERBB2 CCAT1
32 colorectal adenocarcinoma 31.0 ERBB2 EGFR BRAF
33 leukemia, acute myeloid 30.9 TUG1 MALAT1 HOTAIR ERBB2 EGFR CCAT1
34 ovary adenocarcinoma 30.8 ERBB2 EGFR BRAF
35 endometrial adenocarcinoma 30.8 MALAT1 ERBB2 EGFR
36 bladder urothelial carcinoma 30.8 TUG1 MALAT1 HOTAIR GAS5 ERBB2 BRAF
37 pancreatic ductal adenocarcinoma 30.8 MIR375 MALAT1 HOTAIR ERBB2 EGFR AFAP1-AS1
38 suppression of tumorigenicity 12 30.8 ERBB2 EGFR BRAF
39 gastrointestinal stromal tumor 30.7 HOTAIR ERBB2 EGFR BRAF
40 gastric adenocarcinoma 30.7 ROS1 HOTAIR ERBB2 BRAF
41 ovarian epithelial cancer 30.6 MALAT1 HOTAIR CCAT1
42 glioma susceptibility 1 30.3 ERBB2 DGCR5 CYTOR
43 mucinous lung adenocarcinoma 11.4
44 signet ring lung adenocarcinoma 11.4
45 lung papillary adenocarcinoma 11.2
46 tumor predisposition syndrome 11.2
47 lung occult adenocarcinoma 11.1
48 solid adenocarcinoma with mucin production 11.0
49 lung mucinous cystadenocarcinoma 11.0
50 gallbladder cancer 10.9 TUG1 MALAT1 LINC-ROR HOTAIR FENDRR ERBB2

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3
Sources

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

About this section

Clinical features from OMIM®:

612571 (Updated 05-Apr-2021)

Sources

Drugs & Therapeutics for Lung Cancer Susceptibility 3

About this section

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Endostar protein Phase 4
2 Endostatins Phase 4 71581480
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Ipilimumab Approved Phase 3 477202-00-9
7
Ceritinib Approved Phase 3 1032900-25-6
8
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
9
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
10
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
11
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
12
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
15
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
16
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
19
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
20
Cobalamin Experimental Phase 3 13408-78-1 6857388
21 Etoposide phosphate Phase 3
22 Protective Agents Phase 3
23 Shark Cartilage Phase 3
24 2,2'-dithiodiethanesulfonic acid Phase 3
25 Pharmaceutical Solutions Phase 3
26 Immunoglobulins, Intravenous Phase 3
27 Immunoglobulin G Phase 3
28 Endothelial Growth Factors Phase 3
29 Anesthetics Phase 3
30 Liver Extracts Phase 3
31 Vitamin B9 Phase 3
32 Angiogenesis Inhibitors Phase 3
33 Folic Acid Antagonists Phase 3
34 Folate Phase 3
35 Vitamin B Complex Phase 3
36
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
37 Antineoplastic Agents, Immunological Phase 3
38 Vitamins Phase 3
39 Vitamin B12 Phase 3
40 Vitamin B 12 Phase 3
41
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
42
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 2 14838-15-4 26934
43
Trametinib Approved Phase 1, Phase 2 871700-17-3 11707110
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
46
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
47
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
48
Lenvatinib Approved, Investigational Phase 2 417716-92-8
49
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
50
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
2 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
3 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
4 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
5 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
6 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
7 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
8 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Unknown status NCT02281708 Phase 3 vinorelbine plus cisplatin
9 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Unknown status NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
10 Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation Completed NCT01719536 Phase 3 Icotinib;Chemotherapy
11 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
12 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
13 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
14 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
15 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
16 Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
17 Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
18 A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung Completed NCT00455936 Phase 3 Gefitinib
19 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) Recruiting NCT03391869 Phase 3
20 Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
21 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
22 A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
23 A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
24 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT03676192 Phase 3 CT-16;Avastin
25 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
26 Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study Not yet recruiting NCT04339218 Phase 3 Pembrolizumab;Pemetrexed;Carboplatin
27 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
28 A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
29 Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma Terminated NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
30 Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases Terminated NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
31 A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers Unknown status NCT01502202 Phase 2 Gefitinib;Placebo;Pemetrexed plusCIsplatin
32 Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial Unknown status NCT02951637 Phase 2 Pemetrexed plus carboplatin combined with gefitinib;Gefitinib
33 Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma Unknown status NCT02980991 Phase 2 Pemetrexed;Cisplatin
34 A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy Unknown status NCT02787447 Phase 2 TKI;Thymosin Alpha 1
35 Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase â…¡ Study Unknown status NCT02621333 Phase 2 chemotherapy
36 The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Unknown status NCT01564329 Phase 2 endostar
37 Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) Unknown status NCT02946359 Phase 2 Crizotinib, bevacizumab
38 An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations Unknown status NCT03486496 Phase 2 gefitinib;Berberine
39 A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Unknown status NCT03376737 Phase 2 Apatinib
40 Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Unknown status NCT01131429 Phase 2 Erlotinib;Docetaxel;Cisplatin;Docetaxel;Cisplatin;Erlotinib
41 High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Unknown status NCT02284490 Phase 2 pemetrexed
42 Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial Unknown status NCT03728374 Phase 2 Anlotinib
43 Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. Unknown status NCT02704767 Phase 2 Apatinib;Tarceva;Placebo
44 A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma Unknown status NCT02146118 Phase 2 Erlotinib
45 Effectiveness and Safety of Adding Bevacizumab to Chemotherapy in Patients With Advanced Lung Adenocarcinoma With Stable Disease After 2 Cycles of First Line Combination Chemotherapy: a Multicenter, Prospective Cohort Study Unknown status NCT03240549 Phase 2 bevacizumab
46 An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation. Unknown status NCT02036359 Phase 2 erlotinib;docetaxel
47 Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced Gradually Progressed NSCLC After First-line Icotinib: an Open-label, Single-arm, Multicenter Phase II Study Unknown status NCT03402464 Phase 2 Icotinib combined dihydroaremisinin
48 Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases Completed NCT01578668 Phase 2 erlotinib;pemetrexed;cisplatin;erlotinib
49 A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma Completed NCT01588704 Phase 2 Neoadjuvant Bevacizumab
50 A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer Completed NCT01685138 Phase 2 LDK378

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Sources

Genetic Tests for Lung Cancer Susceptibility 3

About this section

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 29
Sources

Anatomical Context for Lung Cancer Susceptibility 3

About this section

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

40
Lung, Breast, Lymph Node, Thyroid, Endothelial, T Cells, Brain
Sources

Publications for Lung Cancer Susceptibility 3

About this section

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 16776)
# Title Authors PMID Year
1
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 54 61 6
12719539 2003
2
Missense mutations of the BRAF gene in human lung adenocarcinoma. 54 61 6
12460919 2002
3
MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. 6 61
25823662 2015
4
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. 61 6
25044103 2014
5
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. 6 61
24569458 2014
6
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 6 61
24327273 2014
7
Acquired resistance to crizotinib from a mutation in CD74-ROS1. 6 61
23724914 2013
8
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. 61 6
22980975 2012
9
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. 6 61
22908275 2012
10
Somatic mutations affect key pathways in lung adenocarcinoma. 61 6
18948947 2008
11
LKB1 modulates lung cancer differentiation and metastasis. 54 6
17676035 2007
12
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
13
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
14
Ceritinib in ALK-rearranged non-small-cell lung cancer. 6
24670165 2014
15
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. 6
22773810 2012
16
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 6
22277784 2012
17
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. 57
21725308 2011
18
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. 6
24212795 2011
19
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. 6
20942962 2010
20
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. 57
19836008 2009
21
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 57
19151717 2009
22
Lung cancer susceptibility locus at 5p15.33. 57
18978790 2008
23
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 57
18978787 2008
24
Somatic mutations of the protein kinase gene family in human lung cancer. 6
16140923 2005
25
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 6
15737014 2005
26
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 6
15457249 2004
27
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
28
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. 61 54
19854534 2010
29
Comparative proteome analysis of human adenocarcinoma. 61 54
19381893 2010
30
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 61 54
20347035 2010
31
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 54 61
20150826 2010
32
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. 61 54
20061363 2010
33
Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. 54 61
20222723 2010
34
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 54 61
19589612 2010
35
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. 61 54
20350214 2010
36
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 54 61
20154720 2010
37
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. 61 54
20146241 2010
38
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation. 54 61
19949890 2010
39
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. 61 54
19540014 2010
40
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. 54 61
19556604 2010
41
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. 61 54
20093391 2010
42
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 54 61
19130320 2010
43
EGFR mutations and the terminal respiratory unit. 54 61
20135199 2010
44
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 61 54
20052735 2010
45
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. 61 54
19947923 2010
46
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. 61 54
20007840 2010
47
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. 54 61
20036260 2010
48
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 61 54
20007486 2010
49
Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. 61 54
19875972 2010
50
ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. 61 54
20003391 2009
Sources

Variations for Lung Cancer Susceptibility 3

About this section

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 398)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRAF NM_004333.6(BRAF):c.1790T>G (p.Leu597Arg) SNV Pathogenic 13968 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
2 ERBB2 NM_004448.3(ERBB2):c.2606T>G (p.Leu869Arg) SNV Pathogenic 431024 rs1131692237 GRCh37: 17:37881414-37881414
GRCh38: 17:39725161-39725161
3 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His) SNV Pathogenic 560007 rs150036236 GRCh37: 7:55259434-55259434
GRCh38: 7:55191741-55191741
4 PRKN and overlap with 1 gene(s) NM_013988.2(PARK2):c.(8_8)_(171_171)+180544del Deletion Pathogenic 7049 GRCh37:
GRCh38: 6:162262766-162727661
5 ERBB2 NM_004448.3(ERBB2):c.2313_2324dup (p.Tyr772_Ala775dup) Duplication Pathogenic 13875 rs397516975 GRCh37: 17:37880981-37880982
GRCh38: 17:39724728-39724729
6 ERBB2 NM_004448.3(ERBB2):c.2328_2336dup (p.Val777_Ser779dup) Duplication Pathogenic 13876 rs587776805 GRCh37: 17:37880998-37880999
GRCh38: 17:39724745-39724746
7 ERBB2 NM_004448.3(ERBB2):c.2263_2264delinsCC (p.Leu755Pro) Indel Pathogenic 13877 rs121913469 GRCh37: 17:37880219-37880220
GRCh38: 17:39723966-39723967
8 EGFR NM_005228.5(EGFR):c.988G>A (p.Glu330Lys) SNV Pathogenic 560008 rs139429793 GRCh37: 7:55223621-55223621
GRCh38: 7:55155928-55155928
9 BRAF NM_001374258.1(BRAF):c.1517G>T (p.Gly506Val) SNV Pathogenic/Likely pathogenic 13967 rs121913351 GRCh37: 7:140481411-140481411
GRCh38: 7:140781611-140781611
10 ROS1 NM_002944.2(ROS1):c.6094G>A (p.Gly2032Arg) SNV Pathogenic/Likely pathogenic 376139 rs1057519788 GRCh37: 6:117638347-117638347
GRCh38: 6:117317184-117317184
11 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
12 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser) SNV Likely pathogenic 376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
13 EGFR NM_005228.5(EGFR):c.2573T>G (p.Leu858Arg) SNV Likely pathogenic 16609 rs121434568 GRCh37: 7:55259515-55259515
GRCh38: 7:55191822-55191822
14 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr) SNV Likely pathogenic 375895 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
15 PIK3CA NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr) SNV Likely pathogenic 376489 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
16 GNAS NM_000516.6(GNAS):c.602G>T (p.Arg201Leu) SNV Likely pathogenic 210045 rs121913495 GRCh37: 20:57484421-57484421
GRCh38: 20:58909366-58909366
17 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
18 PPP2R1A NM_014225.6(PPP2R1A):c.547C>T (p.Arg183Trp) SNV Likely pathogenic 376505 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
19 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val) SNV Likely pathogenic 40387 rs397507483 GRCh37: 7:140453148-140453148
GRCh38: 7:140753348-140753348
20 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys) SNV Likely pathogenic 376470 rs1057519925 GRCh37: 3:178928079-178928079
GRCh38: 3:179210291-179210291
21 GNAS NM_000516.6(GNAS):c.601C>T (p.Arg201Cys) SNV Likely pathogenic 15933 rs11554273 GRCh37: 20:57484420-57484420
GRCh38: 20:58909365-58909365
22 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
23 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Likely pathogenic 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
24 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
25 CDK12 NM_016507.4(CDK12):c.2636G>T (p.Gly879Val) SNV Likely pathogenic 431025 rs1131692238 GRCh37: 17:37665984-37665984
GRCh38: 17:39509731-39509731
26 TP53 NM_000546.5(TP53):c.832C>G (p.Pro278Ala) SNV Likely pathogenic 376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
27 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His) SNV Likely pathogenic 376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
28 TP53 NM_000546.5(TP53):c.585C>G (p.Ile195Met) SNV Likely pathogenic 376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
29 TP53 NM_000546.5(TP53):c.526T>C (p.Cys176Arg) SNV Likely pathogenic 376573 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
30 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu) SNV Likely pathogenic 376673 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
31 TP53 NM_000546.5(TP53):c.709A>G (p.Met237Val) SNV Likely pathogenic 182934 rs730882004 GRCh37: 17:7577572-7577572
GRCh38: 17:7674254-7674254
32 TP53 NM_000546.5(TP53):c.832C>T (p.Pro278Ser) SNV Likely pathogenic 376642 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
33 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely pathogenic 376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
34 TP53 NM_000546.5(TP53):c.584T>A (p.Ile195Asn) SNV Likely pathogenic 376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
35 STK11 NM_000455.4(STK11):c.647C>T (p.Ser216Phe) SNV Likely pathogenic 376708 rs1057520017 GRCh37: 19:1220629-1220629
GRCh38: 19:1220630-1220630
36 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
37 TP53 NM_000546.5(TP53):c.764T>G (p.Ile255Ser) SNV Likely pathogenic 376622 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
38 TP53 NM_000546.5(TP53):c.646G>T (p.Val216Leu) SNV Likely pathogenic 376670 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
39 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
40 TP53 NM_000546.5(TP53):c.715A>G (p.Asn239Asp) SNV Likely pathogenic 234036 rs876660807 GRCh37: 17:7577566-7577566
GRCh38: 17:7674248-7674248
41 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
42 TP53 NM_000546.5(TP53):c.856G>C (p.Glu286Gln) SNV Likely pathogenic 376591 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
43 TP53 NM_000546.5(TP53):c.839G>A (p.Arg280Lys) SNV Likely pathogenic 376657 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
44 TP53 NM_000546.5(TP53):c.745A>T (p.Arg249Trp) SNV Likely pathogenic 141881 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
45 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg) SNV Likely pathogenic 184979 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
46 TP53 NM_000546.5(TP53):c.644G>T (p.Ser215Ile) SNV Likely pathogenic 376660 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
47 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg) SNV Likely pathogenic 376484 rs1057519935 GRCh37: 3:178916945-178916945
GRCh38: 3:179199157-179199157
48 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
49 TP53 NM_000546.5(TP53):c.614A>T (p.Tyr205Phe) SNV Likely pathogenic 376682 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
50 SMAD4 NM_005359.6(SMAD4):c.1156G>A (p.Gly386Ser) SNV Likely pathogenic 376538 rs1057519962 GRCh37: 18:48593405-48593405
GRCh38: 18:51067035-51067035

Cosmic variations for Lung Cancer Susceptibility 3:

9 (show top 50) (show all 35823)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 30
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 30
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 30
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 30
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 30
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 30
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 30
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 30
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 30
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 30
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 30
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 30
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 30
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 30
15 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 30
16 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 30
17 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 30
18 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 30
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 30
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 30
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 30
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 30
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 30
24 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 30
25 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 30
26 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 30
27 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 30
28 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 30
29 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 30
30 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 30
31 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 30
32 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 30
33 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 30
34 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 30
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 30
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 30
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 30
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 30
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 30
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 30
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 30
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 30
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 30
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 30
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 30
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 30
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 30
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 30
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 30
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 30

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
6 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
7 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
8 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
9 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
10 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
11 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
12 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
13 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
14 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
15 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
16 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
17 20853 1 154828181 154830715 Amplification NAXE Lung adenocarcinoma
18 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
19 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
20 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
21 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
22 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
23 24213 1 177317734 177331752 Amplification TOR3A Lung adenocarcinoma
24 24309 1 178523987 178738102 Amplification ACBD6 Lung adenocarcinoma
25 24342 1 178867795 179122103 Amplification XPR1 Lung adenocarcinoma
26 24368 1 179208798 179258669 Amplification STX6 Lung adenocarcinoma
27 25512 1 190800000 193800000 Loss Lung adenocarcinoma
28 25564 1 191332222 191341867 Amplification GLRX2 Lung adenocarcinoma
29 25996 1 195319996 195382287 Amplification ASPM Lung adenocarcinoma
30 26045 1 196138399 196143120 Amplification C1orf53 Lung adenocarcinoma
31 26143 1 197500000 205300000 Amplification RPS10P7 Lung adenocarcinoma
32 27400 1 208022284 208024513 Amplification C1orf74 Lung adenocarcinoma
33 27403 1 208027884 208046105 Amplification IRF6 Lung adenocarcinoma
34 27408 1 208067955 208097531 Amplification UTP25 Lung adenocarcinoma
35 28067 1 218208564 218286623 Amplification EPRS1 Lung adenocarcinoma
36 28340 1 221460783 221604167 Amplification SUSD4 Lung adenocarcinoma
37 28552 1 223183985 223278921 Amplification DNAH14 Lung adenocarcinoma
38 28594 1 223741156 223907468 Amplification ENAH Lung adenocarcinoma
39 29122 1 227795486 227828417 Amplification TAF5L Lung adenocarcinoma
40 29163 1 228269650 228484569 Amplification GALNT2 Lung adenocarcinoma
41 29200 1 228844880 228896351 Amplification COG2 Lung adenocarcinoma
42 29227 1 229108611 229181230 Amplification TTC13 Lung adenocarcinoma
43 29724 1 234780593 234834437 Amplification HEATR1 Lung adenocarcinoma
44 30048 1 239727526 239749677 Amplification FH Lung adenocarcinoma
45 30093 1 240078157 240119671 Amplification EXO1 Lung adenocarcinoma
46 30370 1 242281183 242287403 Amplification ZBTB18 Lung adenocarcinoma
47 38715 10 104423477 104464180 Deletion ARL3 Lung adenocarcinoma
48 40294 10 126620681 126665995 Deletion ZRANB1 Lung adenocarcinoma
49 42230 10 30762871 30790767 Deletion MAP3K8 Lung adenocarcinoma
50 45366 10 70517833 70534573 Deletion SRGN Lung adenocarcinoma
Sources

Expression for Lung Cancer Susceptibility 3

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C1, slow skeletal and cardiac type Lung - 5.28 0.000
2 COL11A1 collagen type XI alpha 1 chain Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end-product specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4 Lung - 4.32 0.000
8 CDH3 cadherin 3 Lung + 4.31 0.000
9 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3 member B Lung - 4.18 0.000
12 FCN3 ficolin 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen type X alpha 1 chain Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 Lung - 3.59 0.000
22 TMPRSS4 transmembrane serine protease 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibril associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP binding cassette subfamily C member 3 Lung + 3.47 0.000
26 TOP2A DNA topoisomerase II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase 4 Lung - 3.38 0.000
29 CYP4B1 cytochrome P450 family 4 subfamily B member 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 Lung + 3.29 0.000
32 NEK2 NIMA related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP binding cassette subfamily A member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin family 1A member 1 Lung - 3.17 0.000
38 VEGFD vascular endothelial growth factor D Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan gamma Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen type I alpha 1 chain Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.
Sources

Pathways for Lung Cancer Susceptibility 3

About this section

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MAPK Pathway 69
Show member pathways
 11.43 ERBB2 EGFR BRAF
2
Bladder cancer 36 1
10.66 ERBB2 EGFR BRAF
3
LncRNA-mediated mechanisms of therapeutic resistance 1
10.03 LINC-ROR HOTAIR
Sources

GO Terms for Lung Cancer Susceptibility 3

About this section

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of kinase activity GO:0033674 9.43 ROS1 ERBB2 EGFR
2 peptidyl-tyrosine phosphorylation GO:0018108 9.26 ROS1 ERBB2 EGFR BRAF
3 negative regulation of ERBB signaling pathway GO:1901185 9.16 ERBB2 EGFR
4 regulation of ERK1 and ERK2 cascade GO:0070372 8.8 ROS1 ERBB2 EGFR

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 ROS1 ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 ROS1 ERBB2 EGFR
3 protein tyrosine kinase activity GO:0004713 8.92 ROS1 ERBB2 EGFR BRAF
Sources

Sources for Lung Cancer Susceptibility 3

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....